Clinical Trial Update: A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome [Phase 1, Phase 2]

View source ↗

Summary

Akeso's AK117 (anti-CD47) is in a Phase 1/2 clinical trial for myelodysplastic syndrome and the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• AK117 (AK117)

Snippet

Sponsor: Akeso | Conditions: Myelodysplastic Syndrome | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING